EUVIMEDEUVIMED entdecken
Crossref

Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention

Arslan Raja

Journal of the Foundations of Ophthalmology · 21.04.2026

DOI: 10.48089/jfo7689135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Foundations of Ophthalmology, online erschienen am 21.04.2026. Verfasst von Arslan Raja.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxychloroquine (HCQ) is widely prescribed in the United Kingdom for autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. Although generally safe, long-term use is associated with a risk of retinal toxicity, which may result in irreversible visual impairment. Hydroxychloroquine retinopathy (HCR) is often asymptomatic in its early stages, making structured screening programmes essential. In response to emerging evidence of higher-than-previously recognised prevalence, the Royal College of Ophthalmologists has developed national guidelines for monitoring. This article reviews the pathophysiology, risk factors, clinical features, UK-based screening recommendations, and management strategies for HCR, with emphasis on prevention and early detection.

Zitieren

APA

Raja, A. (2026). Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention. Journal of the Foundations of Ophthalmology. https://doi.org/10.48089/jfo7689135

Vancouver

Raja A. Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention. Journal of the Foundations of Ophthalmology. 2026. doi:10.48089/jfo7689135

BibTeX
@article{Raja2026,
  author = {Raja, Arslan},
  title = {Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention},
  journal = {Journal of the Foundations of Ophthalmology},
  year = {2026},
  doi = {10.48089/jfo7689135}
}
Kostenlos starten →